UBE3A and Prader-Willi syndrome: Targeting the UBE3A-ATS specifically using modified ASOs was found to successfully unsilence paternal UBE3A without disrupting the expression of the other transcripts implicated in PWS and rescue several disease phenotypes in the AS mouse model (Meng et al., 2015).